EU-India trade deal could derail generic supply chain, MSF warns
This article was originally published in Scrip
Médecins Sans Frontières (MSF) has warned that the stringent intellectual property enforcement and injunction measures in the proposed EU-India free trade agreement (FTA) could have "chilling" implications for the entire generic medicine supply chain. The international NGO says that the free trade agreement as drafted imposes another piece of legislation, the Anti-Counterfeiting Trade Agreement (ACTA), implementation of which would threaten a range of programmes including those funded by the US President's Emergency Plan for AIDS Relief, UNITAID and the Global Fund, and hurting active pharmaceutical ingredients suppliers from India and possibly China.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.